JP2009504135A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504135A5
JP2009504135A5 JP2008510166A JP2008510166A JP2009504135A5 JP 2009504135 A5 JP2009504135 A5 JP 2009504135A5 JP 2008510166 A JP2008510166 A JP 2008510166A JP 2008510166 A JP2008510166 A JP 2008510166A JP 2009504135 A5 JP2009504135 A5 JP 2009504135A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
mammal
virus
protein
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008510166A
Other languages
English (en)
Other versions
JP5303728B2 (ja
JP2009504135A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/016983 external-priority patent/WO2006119363A2/en
Publication of JP2009504135A publication Critical patent/JP2009504135A/ja
Publication of JP2009504135A5 publication Critical patent/JP2009504135A5/ja
Application granted granted Critical
Publication of JP5303728B2 publication Critical patent/JP5303728B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

  1. 配列番号1のアミノ酸配列からなるオリゴアデニレートシンセターゼ1タンパク質であって、1位のメチオニンが欠失しており、162位のアミノ酸がグリシンである、タンパク質。
  2. 哺乳動物におけるウイルス感染を治療または哺乳動物における癌を治療するための治療組成物であって、薬学的に許容される担体と、請求項1に記載のオリゴアデニレートシンセターゼ1タンパク質とを含む、組成物。
  3. 前記ウイルスがフラビウイルスである、請求項2に記載の治療組成物。
  4. 前記ウイルスがC型肝炎ウイルスである、請求項2に記載の治療組成物。
  5. 哺乳動物における癌を治療するための治療組成物であって、請求項1に記載のポリペプチドを、薬学的に許容される担体と共に含む、組成物。
  6. 前記癌が前立腺癌である、請求項5に記載の治療組成物。
  7. 治療化合物がキットの一部として提供される、請求項2に記載の治療組成物。
  8. キットが、治療組成物の使用に関する1以上の指示書または治療組成物の使用に関する規制当局の認可を示す標識もしくは挿入物を含む、請求項7に記載の治療組成物。
  9. 請求項1に記載のタンパク質をコードするポリヌクレオチド。
JP2008510166A 2005-05-04 2006-05-03 Oas1遺伝子内の突然変異 Expired - Fee Related JP5303728B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67768005P 2005-05-04 2005-05-04
US60/677,680 2005-05-04
PCT/US2006/016983 WO2006119363A2 (en) 2005-05-04 2006-05-03 Mutations in oas1 genes

Publications (3)

Publication Number Publication Date
JP2009504135A JP2009504135A (ja) 2009-02-05
JP2009504135A5 true JP2009504135A5 (ja) 2011-05-12
JP5303728B2 JP5303728B2 (ja) 2013-10-02

Family

ID=37113984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008510166A Expired - Fee Related JP5303728B2 (ja) 2005-05-04 2006-05-03 Oas1遺伝子内の突然変異

Country Status (19)

Country Link
US (4) US20060275802A1 (ja)
EP (4) EP2314675B1 (ja)
JP (1) JP5303728B2 (ja)
KR (3) KR20140109510A (ja)
CN (2) CN101203604A (ja)
AU (1) AU2006242152B2 (ja)
BR (1) BRPI0611454A2 (ja)
CA (1) CA2607575A1 (ja)
HK (1) HK1209454A1 (ja)
IL (1) IL187079A (ja)
MX (1) MX2007013765A (ja)
NO (1) NO20076126L (ja)
NZ (1) NZ563785A (ja)
PH (1) PH12014500829A1 (ja)
RU (2) RU2465328C2 (ja)
SG (2) SG175656A1 (ja)
UA (1) UA95446C2 (ja)
WO (1) WO2006119363A2 (ja)
ZA (1) ZA200710521B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2267154A1 (en) 2003-10-23 2010-12-29 Illumigen Biosciences, Inc. Oligoadenylate synthetase
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
US20080038753A1 (en) * 2006-08-01 2008-02-14 Illumigen Biosciences, Inc. Pharmaceutical manufacturing methods
EP2531856A4 (en) 2010-02-05 2013-07-10 Translational Genomics Res Inst METHODS AND KITS USED TO CLASSIFY ADRENOCORTICAL CARCINOMA
CN103536900B (zh) * 2012-07-16 2017-06-16 江苏豪森药业集团有限公司 含有促红细胞生成素模拟肽的药物组合物
WO2016164216A1 (en) * 2015-04-09 2016-10-13 Isp Investments Inc. Method of cosmetic treatment to protect the skin from pollution and improve skin regeneration
CN106483282B (zh) * 2016-09-29 2018-08-31 北京世纪沃德生物科技有限公司 一种抗原稳定剂及其制备方法与应用
WO2020041500A1 (en) * 2018-08-21 2020-02-27 Georgia State University Research Foundation, Inc. Treatment of flavivirus infections in humans using mus musculus resistant 2'-5' oligoadenylate synthetase 1b
US20230083751A1 (en) * 2019-12-30 2023-03-16 Nanjing GenScript Biotech Co., Ltd. Method For Constructing Gene Mutation Library
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
WO2023245177A2 (en) * 2022-06-17 2023-12-21 The University Of Chicago Targeted nanomedicine for treating lung disorders

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863873A (en) * 1980-01-14 1989-09-05 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
DE4039415A1 (de) * 1990-02-03 1991-08-08 Boehringer Mannheim Gmbh Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5266459A (en) * 1992-02-24 1993-11-30 The Scripps Research Institute Gaucher's disease: detection of a new mutation in intron 2 of the glucocerebrosidase gene
DE4208916A1 (de) * 1992-03-20 1993-09-23 Akzo Nv Polyesterfaser und verfahren zu deren herstellung
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5866781A (en) 1993-03-08 1999-02-02 The Cleveland Clinic Foundation Antiviral transgenic plants, vectors, cells and methods
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5597709A (en) * 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
EP0753992A4 (en) 1994-02-18 1998-02-04 Cleveland Clinic Foundation ANTIVIRAL TRANSGENIC PLANTS, VECTORS, CELLS AND METHODS
MX9603936A (es) 1994-03-07 1997-05-31 Inhale Therapeutic Syst Metodos y composiciones para el suministro pulmonar de insulina.
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5514758A (en) 1994-09-30 1996-05-07 The Goodyear Tire & Rubber Company Process for making latex for high performance masking tape
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
JP2001507702A (ja) 1996-12-31 2001-06-12 インヘイル・セラピューティックス・システムズ・インコーポレテッド 親水性賦形剤を有する疎水性薬剤の水性懸濁液を噴霧乾燥させる方法およびその方法によって作製された組成物
US5765887A (en) * 1997-01-07 1998-06-16 P Ii Inc Apparatus and method for searching pockets and crevices
US5993738A (en) * 1997-05-13 1999-11-30 Universal Air Technology Electrostatic photocatalytic air disinfection
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
AU9131698A (en) 1997-09-08 1999-03-29 Princeton University Human genes regulated by human cytomegalovirus and interferon
FR2770300B1 (fr) 1997-10-27 1999-12-31 Vincent Patrice Chritin Dispositif pour la mesure de la vitesse d'un fluide et pour la mesure des flux de particules solides ou liquides dans les fluides ou le vide
WO1999050437A1 (en) * 1998-03-30 1999-10-07 Esa, Inc. Methodology for predicting and/or diagnosing disease
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US20030165921A1 (en) * 2000-02-03 2003-09-04 Tang Y. Tom Novel nucleic acids and polypeptides
WO2001066689A2 (en) 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001245619A1 (en) * 2000-03-09 2001-09-17 Chiron Corporation Human genes and gene expression products
AU2001251613A1 (en) 2000-04-14 2001-10-30 Millennum Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
FR2823224B1 (fr) 2001-04-04 2003-10-31 Pasteur Institut Utilisation de genes oas impliques dans la sensibilite/resistance a l'infection par les flaviviridae pour le criblage de molecules antivirales
WO2002090552A2 (en) 2001-05-08 2002-11-14 Switch Biotech Ag Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
DE10122206A1 (de) 2001-05-08 2002-11-28 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende NukleInsäuren einer 2'-5'- Oligoadenylate Synthetase und/oder RNAseL zur Diagnose, Prävention oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
US6818420B2 (en) * 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
GB0208928D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Methods
US7354908B2 (en) * 2002-04-30 2008-04-08 University Of South Florida Materials and methods for prevention and treatment of RNA viral diseases
JP2006502738A (ja) * 2002-05-17 2006-01-26 ベイラー カレッジ オブ メディスン オリゴアデニレートシンテターゼ様遺伝子の同定
WO2004000998A2 (en) 2002-06-19 2003-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for viral resistance genes
EP2267154A1 (en) 2003-10-23 2010-12-29 Illumigen Biosciences, Inc. Oligoadenylate synthetase
NZ591879A (en) 2003-10-23 2012-11-30 Kineta Two Llc Detection of mutations in a gene associated with resistance to viral infection, OAS1
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1

Similar Documents

Publication Publication Date Title
JP2009504135A5 (ja)
HRP20182195T1 (hr) Sekvence aminokiselina usmjerene protiv virusnih proteina ovojnice i polipeptidi koji sadrže iste za liječenje virusnih bolesti
JP2011530309A5 (ja)
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
EP2460533A3 (en) Yeast-based therapeutic for chronic hepatitis C infection
JP2011528896A5 (ja)
GEP20115248B (en) Hcv ns3 protease inhibitors
IL210455A (en) A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
RU2011106744A (ru) Инсулин, стабилизированный галогеном
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2007531741A5 (ja)
NZ590050A (en) Fgf21 mutants and uses thereof
FI3778885T3 (fi) Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
WO2007119011A9 (fr) Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet
JP2011528895A5 (ja)
EP2186830A4 (en) POLYETHYLENE GLYCOL-MODIFIED ALPHA 2B INTERFERON AND PREPARATION METHOD AND APPLICATIONS THEREOF
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
EP2628749A3 (en) Antimicrobial kinocidin compostions and methods of use
WO2008069917A3 (en) Novel cyclic peptides
RU2012132651A (ru) Мутации в генах oas1
NZ627888A (en) Materials and methods for respiratory disease control in canines
RU2008146997A (ru) Способ блокирования заражения флавивирусами молекулы и применения
JP2006158399A5 (ja) 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections